GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
-4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.26B
AUM Growth
-$362M
(-7.8%)
Cap. Flow
-$2.11M
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17
Top Buys
| 1 |
Philip Morris
PM
|
$43M |
| 2 |
Amazon
AMZN
|
$24.3M |
| 3 |
Palantir
PLTR
|
$16.8M |
| 4 |
Yum China
YUMC
|
$14.4M |
| 5 |
Hims & Hers Health
HIMS
|
$10.9M |
Top Sells
| 1 |
Pinduoduo
PDD
|
$40.6M |
| 2 |
NVIDIA
NVDA
|
$25.7M |
| 3 |
KE Holdings
BEKE
|
$14.3M |
| 4 |
Meta Platforms (Facebook)
META
|
$13.3M |
| 5 |
Coca-Cola
KO
|
$9.83M |
Sector Composition
| 1 | Technology | 42.51% |
| 2 | Consumer Discretionary | 16.26% |
| 3 | Communication Services | 14.17% |
| 4 | Healthcare | 7.8% |
| 5 | Consumer Staples | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CRGX
626
DELISTED
CARGO Therapeutics
CRGX
| $4.65K | ﹤0.01% |
1,142
+176
| +18% | +$716 |
|
627
AC Immune
ACIU
$225M
| $4.59K | ﹤0.01% |
2,454
+377
| +18% | +$705 |
|
628
Voyager Therapeutics
VYGR
$231M
| $4.58K | ﹤0.01% |
1,355
+208
| +18% | +$703 |
|
629
Tevogen Bio Holdings
TVGN
$172M
| $4.54K | ﹤0.01% |
4,207
+531
| +14% | +$574 |
|
630
Neurogene
NGNE
$284M
| $4.31K | ﹤0.01% |
368
+56
| +18% | +$656 |
|
631
Neumora Therapeutics
NMRA
$272M
| $3.88K | ﹤0.01% |
3,883
+491
| +14% | +$491 |
|
|
THRD
632
DELISTED
Third Harmonic Bio
THRD
| $3.88K | ﹤0.01% |
1,118
+172
| +18% | +$597 |
|
633
4D Molecular Therapeutics
FDMT
$332M
| $3.71K | ﹤0.01% |
1,147
+176
| +18% | +$569 |
|
634
Solid Biosciences
SLDB
$425M
| $3.67K | ﹤0.01% |
991
+152
| +18% | +$562 |
|
635
Tango Therapeutics
TNGX
$777M
| $3.65K | ﹤0.01% |
2,665
+410
| +18% | +$562 |
|
|
CMPS
636
Compass Pathways
CMPS
$486M
| $3.61K | ﹤0.01% |
1,261
+193
| +18% | +$552 |
|
637
Larimar Therapeutics
LRMR
$342M
| $3.4K | ﹤0.01% |
1,583
+243
| +18% | +$522 |
|
|
SLN
638
Silence Therapeutics
SLN
$254M
| $3.29K | ﹤0.01% |
1,165
+178
| +18% | +$502 |
|
639
scPharmaceuticals
SCPH
$299M
| $3.27K | ﹤0.01% |
1,242
+191
| +18% | +$502 |
|
640
Nkarta
NKTX
$154M
| $3.22K | ﹤0.01% |
1,751
+269
| +18% | +$495 |
|
641
Alector
ALEC
$302M
| $2.99K | ﹤0.01% |
2,429
+284
| +13% | +$349 |
|
642
Enanta Pharmaceuticals
ENTA
$188M
| $2.9K | ﹤0.01% |
525
+80
| +18% | +$442 |
|
643
Lexeo Therapeutics
LXEO
$277M
| $2.85K | ﹤0.01% |
820
+126
| +18% | +$437 |
|
644
C4 Therapeutics
CCCC
$200M
| $2.8K | ﹤0.01% |
1,751
+269
| +18% | +$430 |
|
645
Editas Medicine
EDIT
$236M
| $2.45K | ﹤0.01% |
2,113
+283
| +15% | +$328 |
|
646
Fate Therapeutics
FATE
$112M
| $2.16K | ﹤0.01% |
2,737
+346
| +14% | +$273 |
|
647
Kyverna Therapeutics
KYTX
$161M
| $2.07K | ﹤0.01% |
1,070
+164
| +18% | +$317 |
|
648
Pliant Therapeutics
PLRX
$106M
| $2.04K | ﹤0.01% |
1,509
+231
| +18% | +$312 |
|
649
MacroGenics
MGNX
$135M
| $1.98K | ﹤0.01% |
1,557
+239
| +18% | +$303 |
|
|
CLYM
650
Climb Bio, Inc. Common Stock
CLYM
$163M
| $1.97K | ﹤0.01% |
1,616
+204
| +14% | +$249 |
|